Merck + Co., Inc.

Michael J Kaufman

William A Hunke

David C Dubost

John M Williams

Jerome P Draper

Maneesh J Nerurkar

Joseph E Lynch

Richard John Varsolona

James A McCauley

Daniel Richard Sidler

Mark Cameron

Yao-Jun Shi

Mandana Asgharnejad

Shyam B Karki

Daniel J Rush

&Ouml;rn Almarsson

Michael A Robbins

Jennifer L Vandrilla

David R Lieberman

Maneesh J Neururkar

David Storey

Jeffrey A Zimmerman

Paul A Bergquist

Lisa M DiMichele

Orn Almarsson

John D Stong

There is disclosed 3-(5-methylisoxazol-3-yl)-6-(1-methyl-1,2,3-triazol-4-yl)methyloxy-1,2,4-triazolo&lsqb;3,4-a&rsqb;phthalazine in the form of a dihydrate, a dehydrate of the dihydrate and a pentahydrate, pharmaceutical compositions comprising the forms, the use of the forms for enhancing cognition, processes for producing the forms, their incorporation in pharmaceutical compositions comprising pamoate ions and the use of such ions for solubilizing neutral molecules.

Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same

Salt form of a conjugate useful in the treatment of prostate cancer

The present invention relates to a novel stabilized form of carbapenem antibiotics of formula II:

Stabilized carbapenem antibiotic compositions and method of making

The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7.

Antifungal compositions

Wet granulation formulation of a growth hormone secretagogue

The invention is a pharmaceutical composition for intravenous administration to a patient comprising

A pharmaceutical composition is disclosed which contains a compound of formula I: ##STR1## or a pharmaceutically acceptable salt, prodrug or hydrate thereof, in the stabilized form and/or in combination with a carbon dioxide source.

Carbapenem antibiotic

This invention is concerned with polymorphic forms of the compound N-�1(R)-�(1,2-dihydro-1-methanesulfonylspiro�3H-indole-3,4'-piperdin!-1'-y l)carbonyl!-2-(phenylmethyloxy)ethyl!-2-amino-2-methylpropanamide methanesulfonate which is a growth hormone secretagogue that is useful in food animals to promote their growth thereby rendering the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, and to treat medical conditions which are improved by the anabolic effects of growth hormone. The instant polymorphic forms have advantages over the other known forms of N-�1(R)-�(1,2-dihydro-1-methanesulfonylspiro�3H-indole-3,4'-piperdin!-1'-y l)carbonyl!-2-(phenylmethyloxy)-ethyl!-2-amino-2-methylpropanamide methanesulfonate in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations. The present invention is also concerned with processes for preparing these polymorphic forms, pharmaceutical formulations comprising these polymorphic forms as active ingredients and the use of the polymorphic form of the compound and their formulations in the treatment of certain disorders.

Polymorphic forms of a growth hormone secretagogue

This invention is concerned with a novel polymorphic form of the compound 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo )methyl)-3-(S)-phenyl-morpholine which is a tachykinin receptor antagonist useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo )methyl)-3-(S)-phenyl-morpholine in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.

Polymorphic form of a tachykinin receptor antagonist

Growing community of inventors

New Hope, PA, United States of America

Michael J Kaufman